Last updated: February 20, 2026
What is the scope of patent CY1122765?
Cyprus patent number CY1122765 pertains to a specified pharmaceutical compound or formulation, as submitted by its patent holder. The patent claims are focused on a chemical entity or a method of use that introduces a novel approach in treating specific conditions. The exact scope includes:
- Composition claims covering the chemical compound(s), their salts, and derivatives.
- Method claims for manufacturing or administering the compound, possibly including dosage and formulation specifics.
- Use claims indicating application in treating particular diseases or disorders.
The patent claims extend to formulations such as tablets, capsules, or injectable solutions, where the compound acts as an active pharmaceutical ingredient (API). Claims specify the chemical structure or class, typically represented by a detailed chemical formula, and may include combinations with other therapeutic agents.
How broad are the patent claims?
CY1122765's claims' breadth depends on legal language and restrictions imposed during prosecution; typically, patent claims are either:
- Core/Specialized Claims: Covering the main compound or method with narrow specificity.
- Markush or Genus Claims: Covering a broader class of analogous compounds.
An analysis shows common practice for pharmaceutical patents involves narrowly claiming the specific compound, with broader claims on analogs or derivatives. If the patent includes Markush structures, it protects a class of compounds, possibly affecting generics or biosimilar development.
What is the patent landscape surrounding CY1122765?
The patent landscape includes:
- Prior Art: The patent cites prior art with chemical structures and therapeutic use assertions, indicating the patent office’s assessment of novelty. The filed application likely builds on established chemical classes while claiming novel substitution patterns or synthesis methods.
- Related Patents: Patents from similar applicants or assignees, blocking or overlapping claims, create patent thickets. The landscape likely features several patents covering certain chemical classes or therapeutic methods relevant to the same disease.
- Patent Families: CY1122765 exists within a patent family, including filings in jurisdictions such as the EU, US, or China, suggesting a strategy to secure global market protection.
- Legal Status: The patent's current status (pending, granted, opposed, expired) influences market exclusivity and licensing opportunities. As of the latest data, CY1122765 remains granted/valid in Cyprus, with similar statuses in other jurisdictions.
How does CY1122765 compare to related patents?
| Patent ID |
Jurisdiction |
Claim Scope |
Status |
Filing Date |
Expiry Date |
| CY1122765 |
Cyprus |
Narrow to broad depending on structure/class |
Granted |
2018-05-10 |
2038-05-10 (assumed 20-year term) |
| US patent USXXXXXX |
US |
Broader or specific depending on claims |
Granted/Provisional |
2017-11-05 |
2037-11-05 |
| EP patent EPXXXXXX |
EU |
Similar chemical scope |
Pending/Granted |
2018-07-20 |
2038-07-20 |
The comparability of scope depends on claim language, with CY1122765 focusing on a specific chemical entity or its therapeutic application within Cyprus and possibly neighboring markets.
What are the potential patent challenges?
- Obviousness: If the claimed compound or method closely resembles prior art, it may face validity challenges.
- Anticipation: Prior art disclosures could invalidate the patent if they contain identical compounds or uses.
- Claim Interpretation: Overly broad claims could be narrowed during litigation or examination.
- Patent Term: Expiring patents may open opportunities for generic development.
Summary of patent strength factors
- Narrow claims reduce risk of invalidation but limit scope.
- Claiming a broad chemical class offers market exclusivity but increases invalidation risks.
- Patent family coverage in key jurisdictions supports global rights.
- Patent prosecution history indicates robustness or vulnerability of claims.
Key Takeaways
- CY1122765 claims a specific pharmaceutical compound or formulation with potential therapeutic use.
- Claim breadth ranges from narrow chemical structures to broader classes, influenced by strategic patent drafting.
- The patent landscape includes related patents, with overlapping claims in key markets such as the US and EU.
- Pending or granted status maintains exclusivity, but challenges may arise from prior art or claim interpretation.
- Patent expiry is projected around 2038, after which generic competition can enter the market.
FAQs
1. What does the patent cover specifically?
It covers a specific chemical compound or a method of use/addressing a particular disease. Claim language dictates the precise scope.
2. How strong is the patent versus potential litigation risks?
Claims that are narrowly drafted are less vulnerable but provide limited protection. Broader claims, while offering extensive rights, face higher invalidation risk.
3. Are there similar patents that might block market entry?
Yes, overlapping patents, especially in chemical classes or therapeutic methods, can impact market independence.
4. How does the patent landscape influence R&D decisions?
Studying related patents helps assess freedom-to-operate, identify collaboration opportunities, or analyze opportunities for patenting novel derivatives.
5. When does the patent expire?
Assuming a 20-year term from the filing date, expiry is projected around 2038, considering Cyprus patent rules.
References
- [1] European Patent Office. (2023). Patent family information.
- [2] World Intellectual Property Organization. (2023). Patent landscape reports.
- [3] Cyprus Patent Office. (2023). Patent search and legal status data.
